Stefano Corda

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications

Efficacy of Vericiguat by Background Guideline-Directed Medical Therapy in the VICTOR Trial.

Efficacy of Vericiguat by Background Guideline-Directed Medical Therapy in the VICTOR Trial.

Journal: European journal of heart failure
Published: July 10, 2026

The effect of vericiguat on sudden cardiac death: insights from the VICTOR trial.

The effect of vericiguat on sudden cardiac death: insights from the VICTOR trial.

Journal: European journal of heart failure
Published: December 21, 2025

Use of soluble guanylyl cyclase stimulators in heart failure therapy-a mode of action perspective.

Use of soluble guanylyl cyclase stimulators in heart failure therapy-a mode of action perspective.

Journal: ESC heart failure
Published: October 10, 2025

Geographic region variation in patient characteristics, clinical outcomes and treatment of HFrEF in the VICTORIA trial.

Geographic region variation in patient characteristics, clinical outcomes and treatment of HFrEF in the VICTORIA trial.

Journal: ESC heart failure
Published: August 07, 2025

Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials.

Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials.

Journal: Lancet (London, England)
Published: July 28, 2025

Effect of Vericiguat on Total Heart Failure Events in Compensated Outpatients With HFrEF: Insights From VICTOR.

Effect of Vericiguat on Total Heart Failure Events in Compensated Outpatients With HFrEF: Insights From VICTOR.

Journal: Journal of the American College of Cardiology
Published: July 28, 2025

Blood pressure, safety and clinical efficacy of vericiguat in chronic heart failure with reduced ejection fraction: Insights from the VICTOR trial.

Blood pressure, safety and clinical efficacy of vericiguat in chronic heart failure with reduced ejection fraction: Insights from the VICTOR trial.

Journal: European journal of heart failure
Published: July 25, 2025

Exploring the potential of soluble guanylyl cyclase stimulators and activators in heart failure.

Exploring the potential of soluble guanylyl cyclase stimulators and activators in heart failure.

Journal: Biochemical pharmacology
Published: July 22, 2025

Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial.

Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial.

Journal: Lancet (London, England)
Published: July 21, 2025

Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial.

Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial.

Journal: European heart journal
Published: July 21, 2025

Assessing Benefit in Patients With Heart Failure and Reduced Ejection Fraction: Analysis of the VICTORIA Trial Using Novel Prognostic Risk Stratification.

Assessing Benefit in Patients With Heart Failure and Reduced Ejection Fraction: Analysis of the VICTORIA Trial Using Novel Prognostic Risk Stratification.

Journal: Journal of cardiac failure
Published: April 22, 2025

Safety and tolerability of a 5 mg starting dose of vericiguat among patients with heart failure: The VELOCITY study.

Safety and tolerability of a 5 mg starting dose of vericiguat among patients with heart failure: The VELOCITY study.

Journal: European journal of heart failure
Published: March 20, 2025
Showing 1-12 of 27

Last Updated: 09/26/2026